Janus

IntelyCare Secures $115 Million Series C Financing Led by Janus Henderson Investors

Retrieved on: 
Wednesday, April 6, 2022

IntelyCare, the leading tech-enabled nurse staffing platform for healthcare organizations in the United States, today announced it has secured $115 million in a Series C financing round led by Janus Henderson Investors, a leading global investment firm and asset manager.

Key Points: 
  • IntelyCare, the leading tech-enabled nurse staffing platform for healthcare organizations in the United States, today announced it has secured $115 million in a Series C financing round led by Janus Henderson Investors, a leading global investment firm and asset manager.
  • The funding, valuing IntelyCare at $1.1 billion, also includes investments by prominent new and existing investors, including Longitude Capital, Leeds Illuminate, Endeavour Vision, Revelation Partners, and Kaiser Permanente Ventures.
  • "In 2016 we began working on a platform to disrupt an industry that was slow to innovate.
  • Since its Series B in February of 2020, IntelyCares annual revenue has grown by more than 850%.

Eisai: Announcement About an Approval for Additional Indication of Jyseleca, JAK inhibitor

Retrieved on: 
Monday, March 28, 2022

The approval of the additional indication is based on the data from Phase IIb/III SELECTION trial evaluating the efficacy and safety of Jyseleca in the induction and maintenance treatment of biologic-naive and biologic-experienced patients with moderately to severely active ulcerative colitis.

Key Points: 
  • The approval of the additional indication is based on the data from Phase IIb/III SELECTION trial evaluating the efficacy and safety of Jyseleca in the induction and maintenance treatment of biologic-naive and biologic-experienced patients with moderately to severely active ulcerative colitis.
  • The trial showed the efficacy and safety profile of Jyseleca, and no new safety risks were identified.
  • With the approval for the additional indication, I expect to see further progress in the treatment of ulcerative colitis."
  • Gilead and EA Pharma, which has been commissioned by Eisai, will co-promote the additional indication of ulcerative colitis.

Janus Henderson to Report First Quarter 2022 Results

Retrieved on: 
Friday, April 1, 2022

Janus Henderson Group plc (NYSE/ASX: JHG) will announce its first quarter 2022 results on Wednesday 4 May 2022 at 4am EDT, 9am BST, 6pm AEST.

Key Points: 
  • Janus Henderson Group plc (NYSE/ASX: JHG) will announce its first quarter 2022 results on Wednesday 4 May 2022 at 4am EDT, 9am BST, 6pm AEST.
  • A conference call and webcast to discuss the results will be held at 8am EDT, 1pm BST, 10pm AEST.
  • Those wishing to participate in the conference call should call the applicable number below and reference the Janus Henderson Results Briefing (Conference ID: 823583):
    To eliminate wait times, conference call participants may pre-register at https://www.incommglobalevents.com/registration/q4inc/10450/janus-hender... .
  • At 31 December 2021, Janus Henderson had approximately US$432 billion in assets under management, more than 2,000 employees, and offices in 25 cities worldwide.

J&J Green Paper Receives Patent Approval for Its Fully Compostable, All-Natural Paper Coating and Process in the United States

Retrieved on: 
Wednesday, March 30, 2022

J&J Green Paper has received U.S. Patent and Trademark Office approval for its cutting-edge green paper solution in the United States.

Key Points: 
  • J&J Green Paper has received U.S. Patent and Trademark Office approval for its cutting-edge green paper solution in the United States.
  • JANUS, developed by J&J, is an all-natural moisture-proof coating used for paper and paper packaging.
  • This organic, recyclable, compostable, repulpable technology directly replaces polyethylene glycol (PEG) currently used in traditional paper products, says Scott Segal, CEO of J&J.
  • J&J is currently in discussions with some of the biggest makers of paper products in the retail, food and beverage industries.

Pfizer Announces Positive Top-line Results from Yearlong Phase 3 Trial of Etrasimod in Ulcerative Colitis, Underscoring Best-in-Class Potential

Retrieved on: 
Tuesday, March 29, 2022

The positive 12- and 52-week results from ELEVATE UC 52 follow the recent announcement of positive 12-week findings from the ELEVATE UC 12 trial on March 23.

Key Points: 
  • The positive 12- and 52-week results from ELEVATE UC 52 follow the recent announcement of positive 12-week findings from the ELEVATE UC 12 trial on March 23.
  • Etrasimod demonstrated a safety profile consistent with previous studies, including the Phase 2 OASIS trial.
  • These data underscore etrasimods potential, if approved, as a best-in-class therapy, said Michael Corbo, Chief Development Officer, Inflammation & Immunology, Pfizer Global Product Development.
  • Etrasimod can potentially provide a new, once-daily, oral option with a rapid onset of action and without first dose titration.

2seventy bio Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Operational Progress

Retrieved on: 
Tuesday, March 22, 2022

2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, today reported financial results and recent highlights for the fourth quarter and year ended December 31, 2021.

Key Points: 
  • 2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, today reported financial results and recent highlights for the fourth quarter and year ended December 31, 2021.
  • Taken together, we expect that we will have a sufficient financial foundation to execute on our patient mission into 2025.
  • Bristol Myers Squibb reported total U.S. ABECMA (idecabtagene vicleucel; ide-cel) fourth quarter revenues of $67 million and full year 2021 U.S. ABECMA revenues of $158 million.
  • The increased financial runway is expected to bring 2seventy bio through meaningful clinical data updates, new INDs and additional commercial progress.

First Trust Dynamic Europe Equity Income Fund Declares its Monthly Common Share Distribution of $0.06 Per Share for April

Retrieved on: 
Monday, March 21, 2022

First Trust Dynamic Europe Equity Income Fund (the "Fund") (NYSE: FDEU) has declared the Funds regularly scheduled monthly common share distribution in the amount of $0.06 per share payable on April 18, 2022, to shareholders of record as of April 4, 2022.

Key Points: 
  • First Trust Dynamic Europe Equity Income Fund (the "Fund") (NYSE: FDEU) has declared the Funds regularly scheduled monthly common share distribution in the amount of $0.06 per share payable on April 18, 2022, to shareholders of record as of April 4, 2022.
  • Under the Plan, the Fund intends to continue to pay a monthly distribution in the amount of $0.06 per share.
  • This distribution may consist of net investment income earned by the Fund, net short-term and long-term capital gains and/or tax deferred return of capital.
  • The Fund is a diversified, closed-end management investment company that seeks to provide a high level of current income.

Lynk Pharmaceuticals and Simcere announced Strategic Commercialization Partnership upon novel JAK1 inhibitor LNK01001

Retrieved on: 
Friday, March 18, 2022

HANGZHOU, China, March 18, 2022 /PRNewswire/ -- On March 18, 2022, Lynk Pharmaceuticals Co., Ltd. (Lynk Pharmaceuticals) and Simcere (2096.HK) announced a strategic partnership to develop and commercialize a highly selective JAK1 inhibitor LNK01001 in China.

Key Points: 
  • HANGZHOU, China, March 18, 2022 /PRNewswire/ -- On March 18, 2022, Lynk Pharmaceuticals Co., Ltd. (Lynk Pharmaceuticals) and Simcere (2096.HK) announced a strategic partnership to develop and commercialize a highly selective JAK1 inhibitor LNK01001 in China.
  • Under the terms of the agreement, Lynk Pharmaceuticals is responsible for the development of the product.
  • Published data of JAK1 inhibitor as treatment of ankylosing spondylitis have shown sufficient superiority of JAK1 inhibitor in a head-to-head study over Humira, the TNF targeting blockbuster.
  • LNK01001 is a highly selective JAK1 inhibitor with therapeutic potential for various autoimmune diseases.

2seventy bio Secures $170 Million in Private Placement Equity Financing

Retrieved on: 
Wednesday, March 16, 2022

Proceeds from the financing will support 2seventy bios ongoing research and development activities as well as general corporate purposes and working capital.

Key Points: 
  • Proceeds from the financing will support 2seventy bios ongoing research and development activities as well as general corporate purposes and working capital.
  • Roughly 100 days into the launch of 2seventy bio, we have taken important steps to secure the companys financial foundation.
  • 2seventy bio ended 2021 with cash, cash equivalents and marketable securities of $362.2 million.
  • 2seventy bio is a trademark of 2seventy bio, Inc.

First Trust Dynamic Europe Equity Income Fund Issues Notice Regarding March 2022 Distribution

Retrieved on: 
Tuesday, March 15, 2022

A return of capital distribution does not necessarily reflect the Fund's investment performance and should not be confused with "yield" or "income."

Key Points: 
  • A return of capital distribution does not necessarily reflect the Fund's investment performance and should not be confused with "yield" or "income."
  • The Fund will send you a Form 1099-DIV for the calendar year that will tell you how to report these distributions for federal income tax purposes.
  • First Trust Advisors L.P. ("FTA") is a federally registered investment advisor and serves as the Fund's investment advisor.
  • FTP is also a distributor of mutual fund shares and exchange-traded fund creation units.